Karo Bio AB (KARO) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 26 PAGES: 40

More Info
									          Karo Bio AB (KARO) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH59487FSA                                                                                          Publication Date: NOV 2012

          Novum, Halsovagen 7                                Phone              +46 8 6086000                   Revenue          NA
          HUDDINGE                                           Fax                +46 8 7748261                   Net Profit       -226.63 (million SEK)
          S-141 57                                           Website            www.karobio.se                  Employees        44
                                                                                KARO       [Stockholm                            Pharmaceuticals           &
          Sweden                                             Exchange                                           Industry
                                                                                Stock Exchange]                                  Healthcare

       Company Overview
       Karo Bio AB (Karo Bio) is a pharmaceutical company that focuses on the research, drug discovery and preclinical development of
       drugs in the therapeutic areas of inflammation, cancer, neuropsychiatry, autoimmune diseases and women's health. The
       company develops new pharmaceuticals based on the nuclear receptors as target protein. The product portfolio of Karo Bio
       consists of four projects in explorative research phase out of which three projects are being conducted in collaboration with other
       pharmaceutical companies.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Karo Bio AB, SWOT Analysis
         Per Bengtsson                       Chief Executive Officer                  Strengths                              Weaknesses
         Christer Fahraeus                   Director
                                                                                                                             No Revenue from Product
         Goran Wessman                       Chairman                                 Sturdy Research and
                                                                                                                             Sales
                                                                                      Development Activities
         Anders Waas                         Director
                                                                                                                             Termination of Development
         Eva Koch                            Deputy Board member                      Significant Partner Projects
                                                                                                                             Programs
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData
                                                                                      Opportunities                          Threats
       Share Data
         Karo Bio AB                                                                  Product Pipeline                       Stringent Regulations
        Share Price (SEK) as on 14-Nov-                                  0.33         Changing Demographics                  Increased Pricing Control
        2012
        EPS (SEK)                                                       -0.59
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million SEK)                                         128         GlobalData

        Enterprise Value (million SEK)                                   123
        Shares Outstanding (million)                                     387
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Oct 24, 2012         Karo Bio Reports Revenue Of SEK8.1m In Q3
                                                                                                           2012
                                                                                      Jul 13, 2012         Karo Bio Reports Revenue Of SEK8.2m In Q2
                                                                                                           2012
                                                                                      May 31, 2012         Karo Bio      Implements      Planned     Efficiency
                                                                                                           Measures
                                                                                      Apr 27, 2012         Karo Bio Reports Net Sales Of SEK8.3m In Q1
                                                                                                           2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Karo Bio AB (KARO) - Financial and Strategic SWOT Analysis                                                                     Reference Code: GDPH59487FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Karo Bio AB - Key Facts ..................................................................................................................................................................... 5
       Karo Bio AB - Key Employees ............................................................................................................................................................ 6
       Karo Bio AB - Key Employee Biographies .......................................................................................................................................... 7
       Karo Bio AB - Major Products and Services ....................................................................................................................................... 8
       Karo Bio AB - Pharmaceutical Pipeline Products Data....................................................................................................................... 9
          Karo Bio AB, Pipeline Products by Therapy Area ........................................................................................................................... 9
          Karo Bio AB, Pipeline Products by Development Phase............................................................................................................... 10
       Karo Bio AB - History ....................................................................................................................................................................... 12
       Karo Bio AB - Company Statement .................................................................................................................................................. 15
       Karo Bio AB - Locations And Subsidiaries........................................................................................................................................ 16
          Head Office ................................................................................................................................................................................... 16
          Other Locations & Subsidiaries ..................................................................................................................................................... 16
       Section 2 – Company Analysis ......................................................................................................................................................... 17
       Karo Bio AB - Business Description ................................................................................................................................................. 17
       Karo Bio AB - Corporate Strategy .................................................................................................................................................... 18
       Karo Bio AB - SWOT Analysis.......................................................................................................................................................... 19
          SWOT Analysis - Overview........................................................................................................................................................... 19
          Karo Bio AB - Strengths ................................................................................................................................................................ 19
             Strength - Sturdy Research and Development Activities ........................................................................................................... 19
             Strength - Significant Partner Projects ...................................................................................................................................... 19
          Karo Bio AB - Weaknesses........................................................................................................................................................... 19
             Weakness - No Revenue from Product Sales ........................................................................................................................... 19
             Weakness - Termination of Development Programs ................................................................................................................. 20
          Karo Bio AB - Opportunities .......................................................................................................................................................... 20
             Opportunity - Product Pipeline .................................................................................................................................................. 20
             Opportunity - Changing Demographics ..................................................................................................................................... 20
          Karo Bio AB - Threats ................................................................................................................................................................... 20
             Threat - Stringent Regulations .................................................................................................................................................. 20
             Threat - Increased Pricing Control............................................................................................................................................. 21
             Threat - Uncertainties in R&D ................................................................................................................................................... 21
       Karo Bio AB - Key Competitors ........................................................................................................................................................ 22
       Section 3 – Company Financial Ratios ............................................................................................................................................. 23
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 23
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 23
       Performance Chart ........................................................................................................................................................................... 25
       Financial Performance...................................................................................................................................................................... 25
       Financial Ratios - Interim Ratios....................................................................................................................................................... 26
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 27
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 28
          Karo Bio AB, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ........................................................................ 28
          Karo Bio AB, Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ........................................................................ 29


Karo Bio AB (KARO) - Financial and Strategic SWOT Analysis                                                                                                     Reference Code: GDPH59487FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Karo Bio AB, Recent Deals Summary .............................................................................................................................................. 30
       Section 5 – Company’s Recent Developments ..............................................................................
								
To top